NCT02547714 - Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 16, 2015

Primary Completion Date

May 2, 2016

Study Completion Date

May 2, 2016

Conditions

Plaque Psoriasis

Interventions

DRUG

Secukinumab (AIN457)

Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.

Trial Locations (11)

Novartis Investigative Site, Nagoya

Novartis Investigative Site, Fukuoka

Novartis Investigative Site, Isehara

Novartis Investigative Site, Osaka

Novartis Investigative Site, Shimotsuke

Novartis Investigative Site, Chiyoda-ku

Novartis Investigative Site, Itabashi-ku

Novartis Investigative Site, Itabashi-ku

Novartis Investigative Site, Minato-ku

Novartis Investigative Site, Shinagawa-ku

Novartis Investigative Site, Shinjuku-Ku